September 27, 2020

The Niche

Knoepfler lab stem cell blog

Editas Medicine

3 min read

It’s notable how the FDA now considers gene-editing a kind of regenerative medicine. This means that various gene therapy products in development technically qualify as regenerative therapies. Ever since the agency began its rapidly growing regenerative medicine advanced therapy (RMAT) designation program, we’ve seen an increasing number of gene therapy biotechs and products qualify as RMATs. As a result, the RMAT-qualified gene therapies get to go into a speedier lane of FDA oversight. Today’s post is a mix of recommended reads in the regenerative …Read More

2 min read

A lot has been going on in the CRISPR world. Here are some key CRISPR updates. Editas has filed the paperwork on the road to going public as a company. Such an IPO, should it come to fruition, could raise billions of dollars. Will the other CRISPR companies like Caribou and CRISPR Therapeutics follow suit? Simplistically, it seems like the first CRISPR IPO could get the lion’s share of investor money, but then there’s the patent thing hanging over all of this (see below) Patent …Read More

3 min read

Google is reportedly getting into the genetic modification business. It plans to use a sexy, new genetic technology called “gene drive”, which has both excited and unsettled scientists due to its great power to make GMOs in nature via reproductive chain reactions. This move toward genetic modification is part of a larger trend of Google and now its parent company Alphabet branching out into biology. Alphabet has said that “G is for Google”, but there could be the letters “G-M-O” in there too. I’m not saying …Read More